PROTACs (PROteolysis TArgeting Chimeras) are bifunctional molecules that target proteins for ubiquitylation by an E3 ligase complex and subsequent degradation by the proteasome. They have emerged as powerful tools to control the levels of specific cellular proteins. We now introduce photoswitchable PROTACs that can be activated with the spatiotemporal precision that light provides. These trifunctional molecules, which we named PHOTACs (PHOtochemically TArgeting Chimeras), consist of a ligand for an E3 ligase, a photoswitch, and a ligand for a protein of interest. We demonstrate this concept by using PHOTACs that target either BET family proteins (BRD2,3,4) or FKBP12. Our lead compounds display little or no activity in the dark but can be reversibly activated with different wavelengths of light. Our modular approach provides a method for the optical control of protein levels with photopharmacology and could lead to new types of precision therapeutics that avoid undesired systemic toxicity.
INTRODUCTION
Protein levels in cells result from a tightly controlled balance between synthesis and degradation. A wide range of small molecules have been identified that interfere with these processes. Most of them do not address specific proteins as they broadly inhibit the machinery nec essary for transcription, translation, trafficking, or degradation. In recent years, PROteolysis TArgeting Chimeras (PROTACs) have emerged as a new principle of pharmacology (1) (2) (3) . These bifunctional molecules combine a ligand for an E3 ubiquitin ligase with a second one that targets a protein of interest (POI), thereby promoting the physical interaction of the proteins, the polyubiquitylation of the POI, and its consequent proteasomal degradation. Both ends of the PROTAC are connected via a linker, the exact nature of which needs to be carefully chosen to ensure efficacy, cell perme ability, and biodistribution.
Firstgeneration PROTACs used peptides to recruit POIs to E3 ligases (4), but subsequent ones have relied on smaller and more cellpermeable synthetic ligands. These include hydroxyproline de rivatives and molecules derived from thalidomide, which bind the von Hippel-Lindau (VHL) protein (5, 6) and cereblon (CRBN) (7, 8) , respectively. VHL and CRBN are the substrate receptors of two cullin RING ubiquitin ligase (CRL) complexes, namely, CRL2 VHL and CRL4 CRBN . Proteins that have been successfully targeted for degradation through these ubiquitin ligases include the androgen and estrogen receptors (9) (10) (11) (12) , the BET family epigenetic readers BRD2-4 (7, 8, 13) , and FKBP12 and its fusion proteins (7, 14, 15) . Soluble kinases, such as cyclindependent kinase 9 (CDK9) (16) and BCRABL (17) , and receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) (18) and Bruton's tyrosine kinase (BTK) (19, 20) , have also been amenable to this approach. Covering a broad spectrum from membrane proteins to nuclear hormone re ceptors, PROTACs have proven to be a highly versatile approach.
PROTACs do not merely inhibit the activity of their targets, like conventional drugs; rather, they decrease the levels of the targets by promoting their proteolysis. The transition from inhibition of pro teins to their catalytic degradation enables the targeting of previously undruggable proteins. However, this mechanistic difference with conventional drugs also poses certain risks when applied systemi cally, since the POI is degraded and disappears with all of its func tions in both cancer and normal cells. For instance, inhibition of BET bromodomains is tolerated, but a complete loss of BRD2 and BRD4 is lethal (21, 22) . Therefore, it would be advantageous to locally ac tivate PROTACs in tissues and cells where their effects (e.g., cyto toxicity) are desirable while avoiding deleterious effects elsewhere.
One method to localize the effect of drugs and achieve higher selectivity is to control their activity with light. In recent years, the usefulness of light to precisely regulate biological pathways has be come increasingly apparent. Optical control can be achieved in a variety of ways: with caged compounds (23) , with genetically engi neered photoreceptors (optogenetics) (24) , or with synthetic photo switches whose activity can be changed through a combination of photochemical isomerization and thermal relaxation (photo pharmacology) (25, 26) .
Here, we report the application of photopharmacology to targeted protein degradation. By incorporating azobenzene photoswitches into PROTACs, we have designed photoswitchable versions that we named PHOTACs (PHOtochemically TArgeting Chimeras). These molecules show little or no proteolytic activity in the dark but can be activated with blueviolet light (380 to 440 nm). They can be used to degrade a variety of targets, including BRD2-4 and FKBP12, by binding to the CRL4 CRBN complex and promoting proteolysis in a lightdependent fashion. This translates to the optical control of protein levels and, in the case of BRD2-4, of cell proliferation, sur vival, and viability. efficient synthetic access. To test the concept, we chose to target CRBN, which, together with VHL, accounts for most of the PROTAC platforms used to date. Accordingly, we focused on thalidomide derivatives, such as pomalidomide and lenalidomide, as CRBN lig ands. As for the photoswitch, we decided to use azobenzenes, which are known for their fatigue resistance, large and predictable geo metrical changes, and easily tunable photothermal properties. Azo benzenes are also among the smallest photoswitches and do not substantially increase the molecular weight of pharmaceuticals upon substitution. Ideal PHOTACs would be inactive in the dark and lead to efficient degradation of the POI upon irradiation. However, the impact of linker conformation on PROTAC activity is not fully un derstood. We therefore explored both regular azobenzenes (more sta ble in their trans form) and diazocines (more stable in cis) (27, 28) .
Several approaches are conceivable for the incorporation of these photoswitches into PHOTACs: (i) They could be part of the ligand for the E3 ligase and change the affinity at this end of the chimera. (ii) The photoswitches could mostly reside in the tether, changing the length and orientation of this segment. (iii) The azobenzenes could be part of a POI ligand, controlling the affinity of the PHOTAC to the POI. It would be difficult, if not impossible, however, to define a strict boundary between ligands and linker, and combinations of all three modes are possible. As for our first POI ligand, we chose (+)JQ1, a highaffinity inhibitor of BET proteins BRD2-4 and BRDT. PROTACs featuring this ligand, such as dBET1 ( Fig. 1B) , have proven to be particularly effective and have been developed for a variety of E3 ligases.
The small library of PHOTACs that resulted from these consid erations is depicted in Fig. 2A . Among these, PHOTAC-I-3 emerged as one of the most effective. Its synthesis started with the diazotiza tion of lenalidomide and coupling of the resulting diazonium ion 1 to 2,6dimethoxyphenol, which yielded azobenzene 2 (Fig. 2B ). Al kylation with tertbutyl bromoacetate and subsequent deprotection then afforded the key intermediate 3. Amide coupling of this car boxylic acid with NBocbutane1,4diamine and deprotection then yielded 4, which underwent another deprotection, followed by peptide coupling with the free acid of (+)JQ1 (5) to afford PHOTAC-I-3. HATU coupling of 3 to diaminoalkanes of different length provided easy access to the library of PHOTACs with varying linker length (i.e., PHOTAC-I-1,2,4,5). PHOTAC-I-6-8, which lack two methoxy groups on the azobenzene core, were synthesized analogously. PHOTAC-I-9 bears a different substitution pattern and was pre pared via BaeyerMills coupling (see the Supplementary Materials). PHOTAC-I-10-13, which have the photoswitch more in the center of the molecule, were synthesized from 4hydroxy thalidomide and azobenzene building blocks via alkylation and amide couplings (see the Supplementary Materials).
The photoswitching and thermal relaxation properties of one of our lead compounds, PHOTAC-I-3, are shown in Fig. 3 (A to E). The optimal wavelength to switch to the cis isomer is 390 nm, but similar photostationary states (PSSs) can be obtained between 380 and 400 nm ( Fig. 3C ). At 390 nm, a PSS of >90% cis could be obtained. Rapid cis to trans isomerization could be achieved by irradiation with wavelengths >450 nm, achieving PSS of ca. >70% trans (Fig. 3C ). In the absence of light, cis-PHOTAC-I-3 slowly isomerized back to its trans form with a halflife of 8.8 hours at 37°C in dimethyl sulfoxide (DMSO) ( Fig. 3D ). Multiple cycles of photo chemical isomerization are possible in keeping with the fatigue resistance of azobenzene photoswitches ( Fig. 3E ). Structurally related PHOTACS showed similar photophysical and thermal properties (see the Supplementary Materials).
Optical control of BRD2-4 with PHOTACs
To assess the biological activity of our PHOTACs, we tested their effect on the viability of RS4;11 lymphoblast cells. Cells were treated in a 96well plate with increasing concentrations of PHOTACs and were either irradiated with 390nm light pulses (100 ms every 10 s) for 72 hours or incubated with the compound in the dark. Sub sequently, we performed cell viability assays (Promega MTS), as previously described. PHOTAC-I-3 showed a promising activity difference upon irradiation (Fig. 4A ). The median effective concen tration (EC 50 ) was determined to be 88.5 nM when irradiated with 390nm light and 631 nM in the dark, resulting in a 7.1fold EC 50 difference. This indicates that cytotoxicity increases upon irradiation and that PHOTAC-I-3 is less toxic in the dark. Similar trends were observed for PHOTAC-I-1,2,4-8,10, all of which were more active in viability assays following pulse irradiation ( fig. S3 ). By contrast, PHOTAC-I-9,11-13 showed no lightdependent differences in ac tivity ( fig. S3 ). In a control experiment, the BET inhibitor (+)JQ1 alone showed no lightdependent toxicity either ( Fig. 4B ). Next, we analyzed the light dependence of targeted protein deg radation in RS4;11 cells by Western blot analysis of the BET pro teins BRD2-4 ( Fig. 5 ). To this end, we treated cells with increasing concentrations of our lead compound, PHOTAC-I-3, for 4 hours and pulse irradiated with 390nm light (100 ms every 10 s). We observed a pronounced decrease in BRD4 levels in the presence of PHOTAC-I-3 (particularly between 100 nM and 3 M) when ir radiated with 390nm light, but not in the dark (Fig. 5A ). At 10 M, we observed less degradation, which is consistent with the "hook effect" commonly observed with PROTACs (5, 19, 29) . BRD3 levels were also greatly reduced upon exposure to concentrations in the range of 100 nM to 3 M of PHOTAC-I-3 when irradiated with violet light, but not in the dark. In comparison, BRD2 was degraded to a lesser extent and within a narrower concentration range. Appli cation of PHOTAC-I-3 (1 M) together with the CRL inhibitor MLN4924 (2.5 M), which inhibits neddylation and, consequently, the activity of all cellular CRLs (including CRL4 CRBN ), rescued BRD2-4 levels upon irradiation. The CRBNdependent degradation was con firmed by a competition experiment ( Fig. 5E ) and further validated by small interfering RNA (siRNA) knockdown of CRBN ( fig. S7 ). Methylation of the glutarimide prevented the degradation of BRD4 as previously demonstrated ( fig. S8 ) (30) .
As expected from photoactivatable degraders and inhibitors of BRD4, cMYC levels were also affected (13, 31, 32) . Downregulation of this transcription factor, which is a notoriously difficult target for pharmacological intervention (33) , was more pronounced when cells were pulse irradiated in the presence of low concentrations of PHOTAC-I-3 than in the dark. The The time dependence of BRD degradation is shown in Fig. 5B . BRD2 and BRD3 are largely absent after 1.5 hours of exposure and irradiation, whereas BRD4 is degraded more slowly. We also observed sustained degradation and cMYC downregulation over 24 hours. In the dark, PHOTAC-I-3 had no effect on BRD levels and rela tively little effect on cMYC levels. The slight effect on cMYC can be explained by inhibition of BRD4 with the (+)JQ1 derivative PHOTAC-I-3 in the absence of targeted degradation. Following sustained pulse irradiation, we also observed increasing cleavage of PARP1 (Fig. 5B ). This indicator of apoptosis (34) One of the principal advantages of photoswitches over caged compounds is their reversibility. Azobenzene photoswitches can thermally relax to an inactive form or be isomerized back photo chemically. We demonstrated the photochemical reversibility with a rescue experiment wherein PHOTAC-I-3 was continuously ir radiated for 1 min with the activating wavelength (390 nm) and then pulse irradiated with the deactivating wavelength (525 nm). Under these conditions, cellular BRD2 levels initially decreased but, sub sequently, recovered faster than when left in the dark (Fig. 5C ).
Another characteristic feature of photopharmacology is "color dosing" (i.e., the ability to control the concentration of the active species with the color of the incident light) (26, 35, 36 (i.e., the ratio between the two isomers) is a function of the wave length. Figures 3A and 5D show that this principle can also be ap plied to PHOTACs. Cell viability assays gave leftshifted curves as the color gradually approached 390 nm (Fig. 4A ). Western blots showed maximum degradation at 390 nm and gradually increasing BRD4 levels as the wavelength of the incident light increased (Fig. 5D ). At 370 nm, we observed slightly increased protein levels, in agree ment with the PSSs measured at different wavelengths, which are maximized toward the active cis isomer at the slightly longer wave length of 390 nm (Fig. 3C) .
The effect of PHOTAC-I-10, which is derived from thalidomide and has the photoswitch positioned deeper in the linker, on BRD4 levels, is shown in Fig. 5E . We found robust photodegradation even with 10 nM PHOTAC-I-10. A clear hook effect was observed. Once again, the thermally less stable cis azobenzene promoted ubiquityl ation and degradation.
Optical control of FKBP12 with PHOTACs
To test whether the PHOTAC approach is generalizable, we turned to the prolyl cistrans isomerase FKBP12. The structures of the cor responding PHOTACs are shown in Fig. 2C . PHOTACs of this series consist of a CRBNtargeting glutarimide, an azobenzene photoswitch in different positions, a linker, and SLF (synthetic ligand of FKBP) that binds to native FKBP12 (7, 14, 37, 38) . The synthesis of PHOTAC-II-1-6 is detailed in the Supplementary Materials. The photophysical and thermal characterization of PHOTAC-II-5 and PHOTAC-II-6 are shown in Fig. 3 (F to H and I to K, respectively).
Among the molecules tested, PHOTAC-II-5 and PHOTAC-II-6 turned out to be the most useful, and our biological investigations have been focused on these molecules (for PHOTAC-II-1-4, see fig. S10 ). PHOTAC-II-5, which has the azobenzene switch in the same position as PHOTAC-I-1-8, had a pronounced effect on FKBP12 levels upon pulse irradiation (Fig. 6A ). The degradation was slower than in the case of BET proteins, but between 6 and 12 hours, the protein was largely absent from our cell lysates (Fig. 6B) . Again, no degradation could be observed in the dark. PHOTAC-II-6, wherein the photoswitch was moved further into the linker region, also elicited lightdependent degradation (Fig. 6C) . The time course of FKBP12 degradation by PHOTAC-II-6 was similar to the one observed with PHOTAC-II-5 (Fig. 6D ). In this case, however, we also observed slight dark activity at the 24hour time point. Both PHOTACs showed a pronounced hook effect and were inactive in the presence of MLN4924.
DISCUSSION
By incorporating photoswitches into PROTACs, we have delineated a general strategy to control targeted protein degradation with the temporal and spatial precision that light affords. As such, we have applied the concept of photopharmacology to an important new target class, i.e., E3 ubiquitin ligases, and have added a highly useful functional feature to existing PROTACs.
As a proof of principle, we developed PHOTACs that combine CRBN ligands with azobenzene photoswitches and ligands for either BET proteins (BRD2,3,4) or FKBP12. The modularity of our approach should enable the straightforward development of PHOTACs that target many other classes of proteins. For instance, existing PROTACs that target CDK4/6 (30), CDK9 (16) , BTK (19, 20) , ABL (17, 39) , ALK (anaplastic lymphoma kinase) (40), MET (18), MDM2 (murine double minute 2) (41), and Tau (42) could be adapted to become light activatable. Our PHOTACs for BRD2,3,4 may enable new in sights into epigenetic pathways and potentially serve as precision tools in medicine. Color dosing and reversibility could be particu larly useful in this regard.
Our PHOTACs for FKBP12 could enable the optical degradation of not only wildtype prolyl cistrans isomerases but also of proteins that are tagged with this domain. This would substantially increase the utility of dTAGs (degradation tags), which have emerged as a broadly applicable technology to influence the homeostasis of fusion proteins (14, 15) . In addition, PROTACs that link thalidomide derivatives to an alkyl halide could be modified to optically degrade proteins fused to a HaloTag domain (43) . Note that some of our photoswitchable thalidomide derivatives, such as synthetic intermediates 2 to 4, and derivatives thereof, could function as dimerizers that recruit Ikaros (IKZF1) and Aiolos (IKZF3) to CRBN in a lightdependent fashion (44) .
The PHOTACs introduced herein have several features that make them useful for biological studies: They are inactive as degraders in the dark and become active upon irradiation. Following activation, they gradually lose their activity through thermal relaxation. Alter natively, they can be quickly inactivated photochemically. In any scenario, their inactivation is much less dependent on dilution, clear ance, or metabolism. In the case of compounds of the PHOTAC-I series, they still function as inhibitors of BET proteins, which explains the cytotoxicity observed in the dark. The concentrations needed for maximum photo effect are low (nanomolar range), substantially reducing possible offtarget effects. The light needed for photo activation is not cytotoxic, given the low intensities needed for photoisomerization and the pulse protocol used (26, 36, 45) .
In principle, light activation of PROTACs could also be achieved with a caging strategy. Caged PROTACs have very recently emerged, complementing PHOTACs (46) . The advantage of the latter lies in their reversibility, the low intensities of light needed to trigger the photochemistry, the ease with which the active concentration can be tuned, and the avoidance of potentially toxic byproducts. Fast relaxing PHOTACs may also provide advantages in terms of local ization and temporal control.
Genetically encoded degrons fused to a photosensitive LOV2 (light oxygen voltagesensing) domain have been reported as an optogenetic approach to protein degradation (47, 48) . Although this approach works well in vivo and provides a powerful method to study biological pathways, it requires transfection with a gene of interest, which limits its therapeutic applicability and can potentially create unphysiological protein levels and distributions within a cell. PHOTACs, by contrast, operate like drugs in native tissues.
An important question to address is how exactly the (E) and (Z) isomers of PHOTACs influence ternary complex formation and target degradation. Although an effect of photoswitching on phar macokinetics cannot be ruled out entirely, the increased activity as a degrader seems to be primarily driven by pharmacodynamics. We consistently observed a hook effect and found no activity when we downregulated CRBN or in the presence of the neddylation inhibitor MLN4924, indicating that PHOTACs function as true PROTACs. Whether the photoswitch primarily affects binding to CRBN or the relative positioning of the E3 ligase and the POI remains to be de termined. Molecular modeling suggests that the (E) configuration of the photoswitch cannot be accommodated as well by CRBN as the (Z) configuration (see fig. S6 ). The importance of the exact na ture, length, and orientation of the linker in PROTACs has been noted ("linkerology") (19, 49, 50) . In keeping with this, we also ob served a pronounced effect of the diamine spacers on our systems. In the series targeting BET proteins, PHOTAC-I-3, which bears a 1,4diamino butane spacer, showed the largest difference between light and dark activity in MTS assays. Related compounds that feature shorter or longer spacers showed smaller or no differences (see fig. S3 ). PHOTAC-I-10, wherein the photoswitch is positioned more centrally, also showed a lightdependent behavior, whereas analogs with dif ferent linker lengths did not. Among compounds targeting FKBP12, the lenalidomide derivative PHOTAC-II-5 and the thalidomide de rivative PHOTAC-II-6, which feature different photo switch incor poration modes, showed the largest light activation. In the case of derivative PHOTAC-II-5, longer linkers were detrimental to optical control (figs. S9 and S10). A satisfying explanation of these observa tions will require detailed biophysical and structural investigations.
The future development of PHOTACs can be taken into many different directions. The incorporation of redshifted and faster relaxing photoswitches could further improve the temporal and spatial precision of darkinactive compounds (51) . Our synthetic approaches are well suited to increase photoswitch diversity. Different ligands for E3 ligases should be explored, for instance, compounds that bind to VHL or the RING ligase MDM2. The optimal position of the photoswitches will depend on the exact nature of the system. Here, we have explored two different modes of photoswitch incor poration, but the third variety (photoswitch in the POI ligand), and combinations thereof, should also be considered. The POI ligand should ideally bind to its target without interfering with its function to cleanly distinguish between degradation and inhibition and to avoid unwanted toxicity.
We anticipate that PHOTACs will be useful tools in cell biology, but we believe that their clinical potential is also worthy of consid eration. Since PROTACs operate in a catalytic fashion and enable systemic protein knockdown, their toxicity is a major concern (52, 53). PHOTACs of the type described herein could be activated with light within a tissue or before administration. They would then lose their activity with a given rate, which can be determined through engi neering of the switch, or they could be actively turned off with a second wavelength. Moreover, PHOTACs locally activated by light would also lose efficacy by dilution, diffusing away from the point of irradiation. The usefulness of light in medicine is well established, and the combination of light and molecules has been studied for decades, e.g., in photodynamic therapy (PDT) (54) . PDT has been applied with encouraging results to treat non-small cell lung cancer, dermatological cancers, and premalignant lesions of the upper di gestive tract and is currently in clinical trials for the treatment of a large variety of other malignancies, including prostate, brain, and breast cancers (54) . In the past, we have used PDT both in cultured cells and in mouse models to induce death of prostate cancer cells in a calciumdependent manner (55) . However, from a molecular point of view, conventional PDT, while effective, is unspecific. PHOTACs, by contrast, can be reversibly activated with the temporal and spatial precision that light affords and target specific proteins whose elim ination would promote cell death. Therefore, we and others (56) believe that PHOTACs may provide a promising new direction in photomedicine.
MATERIALS AND METHODS

Synthesis
The reagents and solvents used in this study were bought from ABCR, Acros Organics, Alfa Aesar, Ark Pharm, CombiBlocks, Oakwood, Oxchem, SigmaAldrich, Strem, and Toronto Research Chemicals and were used as purchased. Dry solvents used in reactions performed under inert atmosphere were obtained by passing the degassed sol vents through activated alumina columns. Column chromatography was carried out on silica gel (pore size, 60 Å; 40 to 63 m; Merck KGaA) using a Teledyne ISCO CombiFlash EZ Prep flash purifica tion system.
Determination of photophysical properties
For ultravioletvisible (UVvis) spectroscopy on the Varian Cary 60 UV Visible spectrophotometer, samples were stored and prepared under red light to avoid the formation of the (Z) isomers. Stock solutions (10 mM) were prepared in the dark and diluted to a final concentration of 25 M for measurement. UVvis spectra of PHOTACs were recorded following irradiation with different wavelengths for 5 min using a monochromator. Measurement was started from the dark adapted state followed by 370 nm irradiation and incrementally increased the wavelength. By increasing the wavelength from low to high, we could observe how much we could switch from (Z) to (E) isomers, whereas going from high to low wavelength, the PSS might not have been attained due to low absorptivity above 500 nm. PHOTAC-I-1-8 were measured in phosphatebuffered saline (PBS) with 10% DMSO, whereas PHOTAC-II-1-6 were measured in DMSO. Thermal relax ation was measured by preirradiating PHOTACs with 390nm light and observing the absorption at 370 nm over 12 hours at 37°C in DMSO in tightly sealed cuvettes.
The reversible switching and photochemical stability of PHOTAC-I-3 were demonstrated in DMSO, cycling the irradiation of the mono chromator between 390 nm (3 min) and 500 nm (7 min). The separated spectra of the (Z) and (E) isomers could be obtained from the internal UVvis detector of the liquid chromatography-mass spectrometry (LCMS) by irradiating the sample before injection and were nor malized at the isosbestic point. In the case of nonsolvochromic pho toswitches, PSSs were calculated in the region of the largest absorption difference between 330 and 390 nm from the separated spectra ob tained by LCMS and the spectra obtained following irradiation with different wavelengths for 5 min, all normalized to the isosbestic point.
LED illumination
For illumination of the cells, we used the cell disco system as previ ously described in the literature (36) . Lightemitting diodes (LEDs) 
Cell culture
The human acute lymphoblastic leukemia RS4;11 (ATCC CRL1873) cell line was purchased from the American Type Culture Collection (ATCC) and cultured in RPMI 1640 medium (Gibco) with 10% fetal bovine serum and 1% penicillin/streptomycin in a humidified incubator at 37°C with 5% CO 2 in air. For the experiments, compounds were serially diluted in RPMI 1640 without the dye phenol red (Gibco) to reduce the influence of the dye by absorption. Azobenzene stocks and dilutions were strictly kept in the dark and prepared under red light conditions. For immunoblotting analysis, cells (2 × 10 6 for RS4:11) were in cubated for the indicated times with PHOTACs, placed in a light proof box, and preirradiated for 1 min at 390 nm followed by 100ms pulses every 10 s or were kept in the dark for 4 hours. After incuba tion, cells were collected in the dark by centrifugation (150g, 5 min) at 4°C, and the pellets were washed twice with icecold PBS (1 ml).
Colorimetric MTS assays
The activity of dehydrogenase enzymes in metabolically active cells, as a quantitative measurement for cytotoxicity and proliferation, was determined by colorimetric measurement of the reduction of MTS to the formazan derivative. The absorbance of formazan at 490 nm was measured on a FLUOstar Omega microplate reader (BMG Labtech). Cells were treated with our compounds at different concentrations, ranging from 10 M to 1 nM/1 pM, (from 10 M to 1 nM/1 pM) in triplicates or sextuplicates, using 1% DMSO as cosolvent, and incubated on a 96well plate for 72 hours. They were placed in lightproof boxes and exposed to the lighting conditions specified in the experiment for 72 hours. Next, 10 l of Promega CellTiter 96 AQ ueous One Solution Reagent was added to each well and incubated for further 4 to 7 hours at 37°C. The absorbance at 490 nm was then recorded with a 96well plate reader.
Data were analyzed using GraphPad Prism version 5.01 (GraphPad Software Inc.) and fitted using the sigmoidal doseresponse (vari able slope) fit. Results represent the mean viability ± SEM relative to the 1% DMSO-treated control.
Immunoblotting analysis
Cells were lysed in radioimmunoprecipitation assay buffer contain ing protease and phosphatase inhibitor, and protein concentration was determined using BCA (Thermo Fisher Scientific). Immuno blotting was performed as previously described (57) . Briefly, samples were resolved under denaturing and reducing conditions using 4 to 12% bistris gels (NuPAGE) and transferred to a polyvinylidene flu oride membrane (ImmobilonP, Millipore). Membranes were blocked with 5% nonfat dried milk and incubated with primary antibodies overnight at 4°C. After washing the membranes, secondary antibodies coupled with horseradish peroxidase were applied (AmershamGE). Immunoreactive bands were visualized by enhanced chemilumines cence reagent (Thermo Fisher Scientific), and signal was acquired using ImageQuant LAS 400 (GE) ( Table 1) . siRNA knockdown of CRBN Realtime polymerase chain reaction (PCR) was performed as pre viously described (55) . For knockdown of CRBN, MBMDA231 cells were seeded 18 hours before transfection. The following ON TARGETplus siRNA oligos from Dharmacon were transfected with Lipofectamine for 8 hours according to the manufacturer's instructions (RNAiMAX, Thermo Fisher Scientific): ONTARGETplus human CRBN SMARTpool (L021086000005) and ONTARGETplus non targeting control siRNA (D0018100105). The medium was replaced, and cells were incubated for 40 hours, upon which they were resub jected to another cycle of siRNA transfection. Medium was replaced, and after 1 hour, the cells were treated with PHOTAC-I-3 or vehicle for 18 hours under pulsed irradiation at 390 nm or in the dark, upon which the cells were collected and subjected to immunoblotting anal ysis as described above. Gene silencing was validated by reverse transcription PCR (RTPCR), isolating total RNA using Qiagen's RNeasy kit (catalog no. 74104). The RT of the mRNA was carried out using 3 g of total RNA using random hexamers and oligo(dT) 18 primers with SMART MMLV Reverse Transcriptase (RNA to cDNA EcoDry Premix, Takara, catalog no. 639549) according to the man ufacturer's instruction. The RTPCR was carried out using PowerUp SYBR Green (Thermo Fisher, catalog no. A25742) with the Thermo Fisher QuantStudio 3 RealTime PCR system in a 96well format. Bar graphs represent the relative ratio of CRBN to glyceraldehyde3 phosphate dehydrogenase (GAPDH) values. The following primers were used for RTPCR: human CRBN (primer set 1) (58) (forward: 5′CCAGTCTGCCGACATCACAT3′, reverse: 5′GTCATCGTG CAAAGTCCTGC3′), human CRBN (primer set 2) (59) (forward: 5′CAGTCTGCCGACATCACATAC3′, reverse: 5′GCACCAT ACTGACTT CTTGAGGG3′), and human GAPDH (forward: 5′TG CACCACCAACTGCTTAGC3′, reverse: 5′GGCATGGACTGT GGTCATGAG3′).
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